Induction therapy in mantle cell lymphoma is rapidly evolving. How do you treat your patients with MCL?
Ibrutinib and acalabrutinib are both active in relapsed MCL. Read how I consider safety, long-term data, and patient preferences when deciding between these BTK inhibitors.
Review practical guidance and the most recent data in this expert analysis of challenging MCL cases, including discussions on when to initiate therapy, how to select optimal first-line treatment, and what to do at progression.
Download the slides from our online module to review expert guidance and recent for management of patients with MCL, including when to initiate therapy and how to select optimal treatment for individual patients.
Use this Interactive Decision Support Tool to compare your choice of therapy for patients with newly diagnosed and relapsed/refractory mantle cell lymphoma with those of 5 renowned experts.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.